Clinical summary
Summary
Stereotactic ablative radiotherapy (SABR) is a specialised form of radiotherapy whereby large doses of radiation are given in fewer treatments. Patients participating in this trial will attend between 6-12 SABR sessions across 2-3 weeks, and will then be followed up regularly post radiotherapy, in order to evaluate treatment safety, quality of life, tumour response and survival.Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Alfred Health
Scientific Title
Treatment of Locally Advanced non-small cell lung carcinoma with Stereotactic ablativE Radiotherapy